Irinotecan Hydrochloride Trihydrate — Drug Intelligence | 58 EU Trials

Filter these 58 trials by condition, phase, country and more.

Open in Search →

58 Registered trials

34 Recruiting

16 Completed trials

40 Sponsors

21 Countries

Phase III

Phase II

Phase III: 20 Phase II/III: 3 Phase II: 27 Phase I/II: 4 Phase III/IV: 1 Phase I (Other): 1 Phase I (FiH): 2

Oversight events:

1 serious breach 5 temporary halts across 2 trials

View oversight register →

Indications tested

Colorectal cancer 4 Rectal cancer 3 Colorectal cancer metastatic 3 Neuroblastoma 2 Cholangiocarcinoma 1 Ewing's sarcoma 1 Rectal adenocarcinoma 1 Desmoplastic small round cell tumour 1 Pancreatic carcinoma 1 Rectal cancer recurrent 1

Sponsors using this IMP

Catharina Ziekenhuis Stichting 6 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 5 AstraZeneca AB 3 IRCCS Istituto Nazionale Tumori Fondazione Pascale 3 Amsterdam UMC 2 Bristol-Myers Squibb Services Unlimited Company 2 Centre Hospitalier Universitaire De Dijon 2 Institut Gustave Roussy 2 Pfizer Inc. 2 1globe Health Institute LLC 1 Amgen Inc. 1 Amsterdam UMC Stichting 1

All trials

58 total

Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study Pending

2024-510617-15-00 Phase III 2 countries Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Neo-adjuvant intraperitoneal chemotherapy (irinotecan) and systemic chemotherapy (mFOLFOX4-bevacizumab) prior to CRS-HIPEC for patients with… Pending

2024-512318-16-00 Phase II 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases – a phase… Pending

2024-517152-34-00 Phase II 1 country Catharina Ziekenhuis Stichting
Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Duct… Pending

2024-518139-12-00 Phase II 1 country Association Gercor
Chemo-immunotherapy before and after surgery for peritoneal metastases of large bowel cancer. Pending

2024-518570-13-00 Phase II/III 2 countries Catharina Ziekenhuis Stichting
A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III … Pending

2024-519031-42-00 Phase III 1 country Associazione Italiana Per Lo Studio Del Pancreas
PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients … Pending

2024-519753-11-00 Phase II 1 country Fondation Franc.Cancerologie Digestive
A Study of S241656 in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies Pending

2025-523474-16-00 Phase I (FiH) 4 countries Institut De Recherches Internationales Servier IRIS
RAGNAR: Refractory Advanced diGestive Neuroendocrine carcinomas treated with tARlatamab Recruiting

2024-514327-42-00 Phase II 2 countries Grupo Espanol De Tumores Neuroendocrinos
Phase II randomized trial to assess the effect of intensive vs standard adjuvant chemotherapy in localised colon cancer with circulating tum… Recruiting

2024-518131-11-02 Phase II 1 country Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospita…
COLLISION RELAPSE trial Recurrent colorectal liver metastases: repeat local treatment +/- neoadjuvant systemic therapy, a phase III prospect… Recruiting

2024-515341-41-01 Phase III/IV 1 country Stichting Amsterdam UMC
ENGIC 02 - PRODIGE 86-FOLFIRINOX SBA- Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanc… Recruiting

2023-505486-92-00 Phase II 2 countries Centre Hospitalier Universitaire De Dijon
Peri-operative intraperitoneal irinotecan and systemic FLOT in the curative treatment of gastric cancer and gastroesophageal junction cancer… Recruiting

2025-522864-34-00 Phase I (Other) 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Previously Untreated, Unresectable, or Met… Recruiting

2025-523224-45-00 Phase II/III 11 countries Bristol-Myers Squibb Services Unlimited Company
Neoadjuvant FOLFOXIRI and Chemoradiotherapy versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, followed by Surgery or a Watch-and-Wait A… Recruiting

2025-523692-39-00 Phase III 1 country Catharina Ziekenhuis Stichting
Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated… Recruiting

2024-515948-23-00 Phase III 1 country Intergroupe Francophone De Cancerologie Thoracique
Phase II study of lurbinectedin and irinotecan in adult and young adult patients with advanced desmoplastic small round cell tumor (DSRCT) Recruiting

2024-519261-21-00 Phase II 2 countries Italian Sarcoma Group
Regorafenib as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, phase 2 study - STREAM-2 Recruiting

2024-519669-23-00 Phase II 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
INTERACT stomach-II Recruiting

2025-521468-36-00 Phase II 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Master Protocol of Novel Study Interventions and Combinations in Participants with Colorectal Cancer Recruiting

2024-518469-84-00 Phase II 5 countries AstraZeneca AB
Systemic antitumor treatment with or without pressurized intraperitoneal aerosol chemotherapy (PIPAC) for colon peritoneal metastases – a mu… Recruiting

2024-514560-10-00 Phase II 1 country Institut De Cancerologie De L Ouest
COSENSE-1: A feasibility study for using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemot… Recruiting

2024-517677-25-00 Phase II 1 country St. Olavs Hospital HF
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Phase III 18 countries Amgen Inc.
Randomized phase 2 study of Valproic acid combinEd with rechallenge anti-EGFR based regimen regimens in pretreated patients with RAS/BRAF wi… Recruiting

2024-514420-16-00 Phase II 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale

Showing 1–24 of 58 trials

← All drugs A–Z